Transplacentar pharmacokinetics of remifentanil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-007972-70-BE

Enrollment

Registered

2008-12-11

Start date

2009-01-22

Completion date

Unknown

Last updated

2022-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transplacentar pharmacokinetics of Remifentanil

Interventions

Trade Name: Ultiva Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: REMIFENTANIL HYDROCHLORIDE CAS Number: 132539072 Concentration unit: mg milligram(s) Concentration ty

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pregnant females who are scheduled for a selective foeticide because of non viabel fetal disorder or intra-uterine fetal blood transfusion Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Maternal contra indication for the use of remifentanil or severe fetal asphyxia

Design outcomes

Primary

Measure	Time frame
Main Objective: to clarify the transplacentar pharmacokinetics of remifentanil during foetoscopic procedures.;Secondary Objective: ;Primary end point(s):	—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026